Topical skin drugs follow the microbial limit standards of Chinese Pharmacopoeia, subject to strict pharmaceutical compliance. Complete GMP rules cover laboratory environment, method verification and out-of-specification investigation.

Cosmetics are regulated by Safety Technical Specifications for Cosmetics (2015 Version), focusing on consumer product hygiene with differentiated limit values and pathogen judgment criteria.

1.Identical Core Test Indexes

Five universal microbial indicators are required for both products: total aerobic bacteria count, total mold and yeast count, thermotolerant coliforms, Pseudomonas aeruginosa and Staphylococcus aureus, to screen pathogens that easily cause skin infections.

2.Distinct Microbial Limits

• Total aerobic count: Uniform limits are set for topical drugs; cosmetics adopt tiered limits, with stricter thresholds for infant, eye and lip products.
• Mold and yeast count: The limit for cosmetics is 100 CFU/g(mL), while topical skin drugs adopt tighter standards.
• Pathogens: Target pathogenic bacteria shall not be detected in either product; any positive result leads to unqualified judgment.

1.Cleanroom Environment

Microbial tests for topical skin drugs must be performed in GMP Class C clean rooms with regular monitoring of settling bacteria and airborne microbes. Cosmetic testing laboratories have relatively loose cleanroom standards with simplified monitoring frequency and records.

2.Supporting Culture Medium

Sterile agar plates, liquid medium and slant tubes are essential for all tests. Culture medium produced by automatic standardized production lines can reduce artificial contamination and stabilize test data, suitable for mass sample testing of drugs and cosmetics.

Once microbial over-limit occurs in topical drugs, full OOS investigation must be launched to trace raw materials, water treatment, filling and cleanroom pollution sources. For cosmetics, rectification focuses on preservative system and workshop sanitation with risk classification management.

Laboratories can share operational experience to optimize sample pretreatment, dilution and incubation procedures and reduce test errors.

Microbiological tests of topical skin drugs and cosmetics share the same goal of preventing skin microbial risks, yet pharmaceutical products carry stricter compliance standards and complete record systems. Laboratories can adopt unified standardized sterile culture medium, and design separate testing workflows according to standard differences to improve testing efficiency and data credibility.